Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Daijiro Harada"'
Autor:
Keisuke Aoe, Shoichi Kuyama, Koji Inoue, Kazuhiro Yatera, Takayuki Suetsugu, Minoru Fukuda, Nobukazu Fujimoto, Kosuke Kashiwabara, Noriyuki Ebi, Fumihiro Tanaka, Daijiro Harada, Akihiro Nishiyama, Chiharu Yoshii, Hitomi Umeguchi, Hironori Yoshida, Atsushi Kawaguchi, Chiho Nakashima, Katsumi Nakatomi, Kentaro Iwanaga, Ayako Takamori, Genju Koh, Naoko Sueoka-Aragane, Nobuhiko Seki, Hidetaka Uramoto, Naohisa Matsumoto, Sunao Ushijima, Kaname Nosaki
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Cancer Medicine
Cancer Medicine
Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or prognostic
Autor:
Yoshinobu Maeda, Naofumi Hara, Naohiro Oda, Eiki Ichihara, Koji Inoue, Shinobu Hosokawa, Daizo Kishino, Katsuyuki Hotta, Nagio Takigawa, Katsuyuki Kiura, Daijiro Harada, Takuo Shibayama, Shingo Harita, Nobuaki Ochi
Publikováno v:
European Journal of Cancer. 157:523-524
Autor:
Akihiro Bessho, Toshiyuki Kozuki, Katsuyuki Hotta, Hiroshige Yoshioka, Nagio Takigawa, Ichiro Takata, Shinobu Hosokawa, Daijiro Harada, Toshihide Yokoyama, K. Kiura, Hideko Isozaki
Publikováno v:
Journal of Thoracic Oncology. 16:S655-S656
Autor:
Naoyuki Nogami, Daijiro Harada
Publikováno v:
Nihon Naika Gakkai Zasshi. 106:1108-1116
Autor:
Masahiro Morise, Hibiki Udagawa, Ryota Ushio, Terufumi Kato, Daijiro Harada, Masato Shingyoji, Ryo Toyozawa, Shogo Nomura, Noboru Yamamoto, S. Hara, Akihiro Sato, Saori Takata, Haruko Daga, Takaya Ikeda, Shigeki Umemura, Toshiaki Takahashi, Shingo Matsumoto, Seiji Niho, Koichi Goto, Jun Sakakibara-Konishi
Publikováno v:
Journal of Clinical Oncology. 38:9064-9064
9064 Background: Development of targeted therapy for SCLC based on a large-scale genomic screening is an innovative challenge. Gedatolisib is a highly potent dual inhibitor of PI3K/mTOR and is expected to have an effect for tumors with PI3K/AKT/mTOR
Autor:
Naoyuki Nogami, K. Kiura, Nobuaki Ochi, Kenichi Chikamori, Akihiro Bessho, Nobukazu Fujimoto, Shoichi Kuyama, T. Umeno, G. Ikeda, Katsuyuki Hotta, Daizo Kishino, Daijiro Harada, Nagio Takigawa, Kiichiro Ninomiya
Publikováno v:
Annals of Oncology. 28:x139-x140
Autor:
Nobuyuki Katakami, Akito Hata, Reiko Kaji, Yoshika Takechi, Chiyuki Okuda, Naoyuki Nogami, Toshiyuki Kozuki, Yoshio Masuda, Daijiro Harada
Publikováno v:
Oncotarget
// Akito Hata 1 , Daijiro Harada 3 , Chiyuki Okuda 1 , Reiko Kaji 1 , Yoshio Masuda 2 , Yoshika Takechi 4 , Toshiyuki Kozuki 3 , Naoyuki Nogami 3 and Nobuyuki Katakami 1 1 Department of Medical Oncology, Kobe City Medical Center General Hospital, Kob
Autor:
Kenichiro Kudo, Toshio Kubo, Hiromi Watanabe, Masahiro Tabata, Eiki Ichihara, Kiichiro Ninomiya, Katsuyuki Kiura, Katsuyuki Hotta, Etsuko Murakami, Daisuke Minami, Takashi Ninomiya, Daijiro Harada, Kadoaki Ohashi, Masayuki Yasugi, Nobuaki Ochi, Yoshinobu Maeda, Keiichi Fujiwara
Publikováno v:
Journal of Clinical Oncology. 36:e21147-e21147
e21147Background: Several kinds of immune checkpoint inhibitors (ICIs) have demonstrated longer survival compared with chemotherapy in advanced non-small cell lung cancer (NSCLC). However, the effe...
Autor:
Eiki Ichihara, Kiichiro Ninomiya, Yoshinobu Maeda, Takashi Ninomiya, Kenichiro Kudo, Toshio Kubo, E. Murakami, Kadoaki Ohashi, Masayuki Yasugi, Hiromi Watanabe, Masahiro Tabata, Keiichi Fujiwara, Nobuaki Ochi, Daijiro Harada, Katsuyuki Hotta, Daisuke Minami, K. Kiura
Publikováno v:
Journal of Clinical Oncology. 36:e21034-e21034
e21034Background: Immune checkpoint inhibitors (ICIs) offer longer survival than chemotherapy in advanced non-small cell lung cancer (NSCLC). In subset analyses, ICIs extended survival compared to ...
Autor:
Nagio Takigawa, Shinobu Hosokawa, Kiichiro Ninomiya, Mitsune Tanimoto, Kenichi Chikamori, Shoichi Kuyama, Hiroshi Ueoka, Akihiro Bessho, Katsuyuki Kiura, Nobukazu Fujimoto, Shingo Harita, Katsuyuki Hotta, Genyo Ikeda, Daijiro Harada, Nobuaki Ochi, Daizo Kishino, Naoyuki Nogami, Takahiro Umeno
Publikováno v:
Journal of Clinical Oncology. 35:e20614-e20614
e20614 Background: S-1 is an oral fluoropyrimidine anticancer agent that combines tegafur, gimeracil, and oteracil potassium. Two phase III trials in advanced non-small cell lung cancer (NSCLC) showed the non-inferiority of combination of S-1 with ca